Key result
Inhibition of the chromatin factor KAT5 significantly attenuated fibrotic responses, including α-SMA expression and collagen secretion, in both murine and patient-derived human cardiac fibroblasts.
Why the study?
The roles of chromatin factors in myofibroblast differentiation and their contribution to pathogenic cardiac fibrosis remain poorly understood.
Identification of Srcap and Kat5 as key epigenetic regulators of cardiac fibrosis suggests KAT5 inhibition as a potential therapeutic target for pathogenic cardiac fibrosis.
Srcap and Kat5 emerge as pro-fibrotic chromatin regulators in cardiac fibroblasts; hypothesis-generating for epigenetic antifibrotic targets.
Cardiac fibrosis is mediated by the persistent activity of myofibroblasts, which differentiate from resident cardiac fibroblasts in response to tissue damage and stress signals. The signaling pathways and transcription factors regulating fibrotic transformation have been thoroughly studied. In contrast, the roles of chromatin factors in myofibroblast differentiation and their contribution to pathogenic cardiac fibrosis remain poorly understood. Here, we combined bulk and single-cell CRISPR screens to characterize the roles of chromatin factors in the fibrotic transformation of primary cardiac fibroblasts. We uncover strong regulators of fibrotic states including Srcap and Kat5 chromatin remodelers. We confirm that these factors are required for functional processes underlying fibrosis including collagen synthesis and cell contractility. Using chromatin profiling in perturbed cardiac fibroblasts, we demonstrate that pro-fibrotic chromatin complexes facilitate the activity of well-characterized pro-fibrotic transcription factors. Finally, we show that KAT5 inhibition alleviates fibrotic responses in patient-derived human fibroblasts.
No takes yet. Share an insight, caveat, or question.
Aguado‐Alvaro et al. (2025) studied Cardiac fibrosis. KAT5 inhibition (genetic knockout or chemical inhibitor NU-9056) vs. Non-targeting control or vehicle was evaluated on Fibrotic transformation (measured by alpha-SMA expression, collagen secretion, and PDGFRα levels). Inhibition of the chromatin factor KAT5 significantly attenuated fibrotic responses, including α-SMA expression and collagen secretion, in both murine and patient-derived human cardiac fibroblasts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: